Axicabtagene ciloleucel,Cyclophosphamide,Fludarabine
gilead
['axi-cel']
axi-cel's curative potential is supported by a 41.8% progression-free survival at 4 years with median 47 month follow up reassuringly few relapses after the 6 month mark. #asco23 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem